# NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction

Study · id `cardio:ct-nct02557217` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02557217](<https://clinicaltrials.gov/study/NCT02557217>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02557217

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT02557217. Randomized; quadruple masking; primary purpose treatment. Start 2015-10 (registry gives no type); primary completion 2017-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT02557217, source copy `cardio:ctgov-nct02557217-2017-06-28`, retrieved 2026-10-26)
- Start date: 2015-10 (registry gives no type) (ClinicalTrials.gov record NCT02557217, source copy `cardio:ctgov-nct02557217-2017-06-28`, retrieved 2026-10-26)
- Primary completion: 2017-12 (anticipated) (ClinicalTrials.gov record NCT02557217, source copy `cardio:ctgov-nct02557217-2017-06-28`, retrieved 2026-10-26)
- Completion: 2018-02 (anticipated) (ClinicalTrials.gov record NCT02557217, source copy `cardio:ctgov-nct02557217-2017-06-28`, retrieved 2026-10-26)
- Countries: Australia (ClinicalTrials.gov record NCT02557217, source copy `cardio:ctgov-nct02557217-2017-06-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02557217-2017-06-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction
- Condition: ST Elevation Myocardial Infarction
- Intervention (Drug): NP202
- Intervention (Other): Placebo
- Lead sponsor: Armaron Bio Pty Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Calcium/Calmodulin-Dependent Protein Kinase II Delta Inhibition and Ventricular Remodeling After Myocardial Infarction: A Randomized Clinical Trial (`cardio:pubmed-33851966`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 1cd2690efdbb55b4833f467837b8cdcb31c9e2463c1253b665d5b8534f3e1c06
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
